

**p16 (Clone: JC8)
Mouse Monoclonal Antibody**

PRODUCT INFORMATION:

MM1240 6ml Ready to use
MM1240 3ml Ready to use
MMC1240 1ml Concentrated
MMC 1240 0.5ml Concentrated
MMC 1240 0.1ml Concentrated
MMH1240 6ml Ready to use
MMH1240 3ml Ready to use

PERFORMANCE CHARACTERISTICS:

Localization: Nucleus & Cytoplasm
Retrieval Buffer: Tris-EDTA, pH 9.0
Incubation: 30-60 minutes
Positive control: Cervical Ca

INTENDED USE

For research use only

This antibody is intended for use in qualitatively identify p16 antigen by light microscopy in formalin fixed, paraffin embedded (FFPE) tissue sections using immunohistochemical (IHC) detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper known controls (Positive and Negative) and must be made within the context of the patient's clinical history and other diagnostic tests. A qualified and trained pathologist must perform evaluation of the test. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using nonimmunologic histochemical stains.

SUMMARY AND EXPLANATION

The progression of cells through the cell cycle is regulated by a family of protein kinases known as cyclin-dependent kinases (Cdks). The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle. The cyclins function is differentially expressed positive regulators of Cdks. Negative regulators of the cycle include the p53-inducible protein p21 (also designated WAF1 or Cip1), Kip1 p27 and p16. The complexes formed by Cdk4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase. It has been shown that p16 binds to Cdk4 and inhibits the catalytic activity of the Cdk4/cyclin D complex. Moreover, the gene encoding p16 exhibits a high frequency of homozygous deletions and point mutations in established human tumor cell lines.

PRINCIPLE OF THE PROCEDURE

The identification of the antigen on the FFPE tissues is carried out using the above stated antibody. The antigen and antibody complex is visualized using an enzyme coupled (HRP/AP) secondary antibody with specific binding to the primary antibody, this complex is visualized by the enzymatic activation of the chromogen resulting to a visible reaction production of the antigenic site. Each and every step involves precise time and optimal temperature and the results are interpreted using a light microscope by a qualified and trained pathologist.

REAGENT PROVIDED

Concentrated format: Antibody to p16 is affinity purified and diluted in antibody diluent with 1% bovine serum albumin (BSA) and 0.05% of sodium azide (NaN₃).
Recommended dilutions: 1:50 – 1:100
 The antibody dilution and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be determined by individual laboratory.
Pre-diluted format: PathnSitu's ready to use antibodies are pre-titrated to optimal staining conditions. Further dilution will affect the efficacy of the antibody and may yield to sub-optimal staining.
Immunogen: p16INK4A (JC8) is a mouse monoclonal antibody raised against full length recombinant p16 INK4A of human origin.
Host, Isotype: Mouse, IgG2a

STORAGE AND HANDLING

Storage Recommendations: Store at 2-8°C. When stored at the appropriate conditions, the antibody is stable until expiry. Do not use the antibody after expiration date provided on the vial in any condition.
 To ensure proper reagent delivery and stability, replace the dispenser cap after every use and immediately place the vial into the refrigerated conditions in an upright position. The contents of the vial should be used within 9 months from the opening of the vial.

SPECIMEN PREPARATION

Staining Recommendations:

Routinely processed, FFPE tissues are suitable for use with this primary antibody, when used PathnSitu's Poly Excel HRP/DAB detection system. The recommended tissue fixative is 10% neutral buffered formalin. Variable results may occur as a result of prolonged fixation or special processes such as decalcification. Thickness of the sections should be 2-5µm. Slides should be stained once the sections are made as antigenicity of the cut sections may diminish over a period of time. It is recommended to stain known positive and negative controls simultaneously with unknown specimens.

PRECAUTIONS

1. This product should be used by qualified and trained professional users only
2. The product contains < 0.1% of sodium azide as preservative and is not classified hazardous, refer MSDS for further details
3. As with any product derived from biological sources, proper handling procedures should be used
4. Do not use reagents after expiration date
5. Use protective clothing and gloves, while handling reagents
6. All hazardous materials should be disposed according to local state and federal regulations
7. Avoid microbial contamination of reagents as it may lead to incorrect results

STAINING PROCEDURE

Antigen Retrieval Solution: Use Tris-EDTA Buffer (Cat#PS009) as antigen retrieval solution.

Heat Retrieval Method: Retrieve sections under steam pressure for 15 minutes using PathnSitu's MERS (Multi Epitope Retrieval System) for optimal retrieval of the epitopes, allow solution to cool at the room temperature, transfer the tissue sections/slides to the distilled water prior to the primary antibody application.

Primary Antibody: Cover the tissue sections with primary antibody and incubate for 30-60 min at room temperature when used PathnSitu's PolyExcel Detection System.

Detection System: Refer to PathnSitu's PolyExcel HRP/ DAB detection system protocol for optimal staining results.

QUALITY CONTROL

The recommended positive tissue control for p16 is Cervical Carcinoma. A positive and negative tissue control must be run with every staining procedure performed for monitoring the correct performance of processed tissue and test reagents. A negative tissue controls provide an indication of non-specific background staining. If the results are not expected in positive and negative controls the test must be considered invalid and entire procedure must be cross verified. Individual laboratory must establish their own quality control to validate the process and antibody when opened a vial.

INTERPRETATION OF RESULTS

p16 stains Nucleus and Cytoplasm. A qualified experienced/trained pathologist must interpret the results in the patient's sample along with the positive and negative controls.

PERFORMANCE CHARACTERISTICS

PathnSitu products will undergo a thorough quality control check before it is released to the market. The antibody showed consistent specific and sensitive staining on the multiple positive tissue controls tested, by inter run, intra run and lot based studies. The antibody is stable for the expiry mentioned on the labels which is determined by real time or accelerated methods.

TROUBLESHOOTING

1. Follow the antibody specific protocol recommendations according to data sheet provided
2. Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, tissue processing, antibody freezing and thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids may produce artifacts, antibody trapping or inaccurate results
3. Do not allow the section to dry out during the entire IHC process
4. Excessive or incomplete counterstaining may compromise the interpretation of the results

5. If unusual results occur, contact PathnSitu's Technical Support at +91-40-2701 5544 or E-mail: techsupport@pathnsitu.com

LIMITATIONS AND WARRANTY

Authorized and skilled/trained personnel only may use the product. The clinical interpretation of any test results should be evaluated within the context of the patient's medical history and other diagnostic test results. A qualified trained pathologist must perform the evaluation of the test results. There are no warranties, expressed or implied, which extend beyond the description. PathnSitu is not liable for property damage, personal injury, time or effort on economic loss caused by this product.

BIBLIOGRAPHY

1. Drayton, S., et al. 2003. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. *Cancer Cell* 4: 301-310.
2. Moore, L.M., et al. 2009. IGFBP2 is a candidate biomarker for Ink4a-Rb status and a therapeutic target for high-grade gliomas. *Proc. Natl. Acad. Sci. USA* 106: 16675-16679.
3. Xue, Y., et al. 2010. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. *Cancer Res.* 70: 5316-5325.
4. Kreiling, J.A., et al. 2011. Age-associated increase in heterochromatic marks in murine and primate tissues. *Aging Cell* 10: 292-304.
5. Wild, P.J., et al. 2012. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumor aggressiveness in humans. *EMBO Mol. Med.* 4: 808-824.
6. Kaplon, J., et al. 2013. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. *Nature* 498: 109-112.
7. Sasai, N., et al. 2013. The transcriptional cofactor MCAF1/ATF7IP is involved in histone gene expression and cellular senescence. *PLoS ONE* 8: e68478.
8. Iannetti, A., et al. 2014. Regulation of p53 and Rb links the alternative NFκB pathway to EZH2 expression and cell senescence. *PLoS Genet.* 10: e1004642.
9. Lenain, C., et al. 2015. Autophagy-mediated degradation of nuclear envelope proteins during oncogene-induced senescence. *Carcinogenesis* 36: 1263-1274.

EXPLANATION OF SYMBOLS


LOT- Lot number / Batch number



- Expiry

RUO

Research use only



Storage limitation